Variables | ||
---|---|---|
Age (year, mean ± SD) | 65.9 ± 9.4 | |
Sex | Male | 72 (78.3%) |
Female | 20 (21.7%) | |
Siewert classification | Type I adenocarcinoma | 2 (2.2%) |
Type II adenocarcinoma | 16 (17.4%) | |
Type III adenocarcinoma | 11 (12.0%) | |
Not applicable | 63 (68.5%) | |
Macro type | Type 0 | 36 (39.1%) |
Type 1 | 4 (4.3%) | |
Type 2 | 26 (28.3%) | |
Type 3 | 21 (22.8%) | |
Type 4 | 1 (1.1%) | |
Type 5 | 4 (4.3%) | |
Preoperative chemotherapy | No | 79 (85.9%) |
Yes | 13 (14.1%) | |
Extent of surgical resection | Subtotal esophagectomy with partial gastrectomy | 14 (15.2%) |
Proximal gastrectomy with partial esophagectomy | 30 (32.6%) | |
Total gastrectomy with partial esophagectomy | 48 (52.2%) | |
Extent of lymph node dissection | Abdominal, mediastinal and cervical | 11 (12.0%) |
Abdominal and mediastinal | 9 (9.8%) | |
Abdominal and lower mediastinal† | 27 (29.3%) | |
Abdominal | 45 (48.9%) | |
Pathological tumor size (mm, mean ± SD) | 46.1 ± 23.7 | |
Main histologic type | Adenocarcinoma | 79 (85.9%) |
Squamous-cell carcinoma | 13 (14.1%) | |
Lymphatic invasion | L0 | 32 (34.8%) |
L1 | 60 (65.2%) | |
Venous invasion | V0 | 32 (34.8%) |
V1–2 | 60 (65.2%) | |
Pathological depth of tumor invasion | pT1 | 33 (35.9%) |
pT2 | 11 (12.0%) | |
pT3 | 35 (38.0%) | |
pT4 | 13 (14.1%) | |
Lymph node metastasis | pN0 | 47 (51.1%) |
pN1 | 19 (20.7%) | |
pN2 | 14 (15.2%) | |
pN3 | 12 (13.0%) | |
Distant metastasis | pM0 | 72 (78.3%) |
pM1 | 20 (21.7%) | |
TNM stage | pStage I | 36 (39.1%) |
pStage II | 19 (20.7%) | |
pStage III | 17 (18.5%) | |
pStage IV | 20 (21.7%) | |
Adjuvant chemotherapy | No | 43 (46.7%) |
Yes | 49 (53.3%) |